Evidence map›Paper›PMID 39522034›Full record

ArticleStem cell research & therapy2024

Mesenchymal stem cells: a novel therapeutic approach for feline inflammatory bowel disease.

Qiyun Xie, Saisai Gong, Jintao Cao, Aoyun Li, Md F Kulyar, Bingyun Wang, Jiakui Li

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Nutrients · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Mesenchymal Stem Cells in Veterinary Medicine-Still Untapped Potential.Animals : an open access journal from MDPI · 2025
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qiyun Xie *College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, 430070, P.R. China.
Saisai Gong *College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, 430070, P.R. China.
Jintao CaoCollege of Veterinary Medicine, Huazhong Agricultural University, Wuhan, 430070, P.R. China.
Aoyun LiCollege of Veterinary Medicine, Henan Agricultural University, Zhengzhou, P.R. China.
Md F KulyarCollege of Veterinary Medicine, Huazhong Agricultural University, Wuhan, 430070, P.R. China.
Bingyun WangSchool of Life Science and Engineering, Foshan University, Foshan, P.R. China. bywang63@163.com.
Jiakui LiCollege of Veterinary Medicine, Huazhong Agricultural University, Wuhan, 430070, P.R. China. lijk210@mail.hzau.edu.cn.ORCID 0000-0002-6065-6648

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammatory bowel disease (IBD) poses a significant and growing global health challenge, affecting both humans and domestic cats. Research on feline IBD has not kept pace with its widespread prevalence in human populations. This study aimed to develop a model of feline IBD by incorporating dextran sulfate sodium (DSS) to evaluate the therapeutic potential of MSCs and to elucidate the mechanisms that enhance their action.

methodsWe conducted a comprehensive clinical assessment, including magnetic resonance imaging (MRI), endoscopy, and histopathological examination. Additionally, alterations in intestinal microbiota were characterized by 16 S rDNA sequencing, and the influence of MSCs on IBD-related gene expression was investigated through transcriptome analysis.

resultsAccording to our findings, MSC treatment significantly mitigated DSS-induced clinical manifestations, reduced inflammatory cell infiltration, decreased the production of inflammatory mediators, and promoted mucosal repair. Regarding the intestinal microbiota, MSC intervention effectively corrected the DSS-induced dysbiosis, increasing the presence of beneficial bacteria and suppressing the proliferation of harmful bacteria. Transcriptome analysis revealed the ability of MSCs to modulate various inflammatory and immune-related signaling pathways, including cytokine-cytokine receptor interactions, TLR signaling pathways, and NF-κB pathways.

conclusionThe collective findings indicate that MSCs exert multifaceted therapeutic effects on IBD, including the regulation of intestinal microbiota balance, suppression of inflammatory responses, enhancement of intestinal barrier repair, and modulation of immune responses. These insights provide a solid scientific foundation for employing MSCs as an innovative therapeutic strategy for IBD and pave the way for future clinical explorations.

Indexed as

Inflammatory Bowel DiseasesMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsCat DiseasesCatsDextran SulfateDisease Models, AnimalGastrointestinal MicrobiomeDextran SulfateCat modelInflammatory bowel diseaseIntestinal microbiotaMesenchymal stem cells (MSCs)

Identifiers

PMID39522034
PMCPMC11550560

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.